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edu.https://doi.org/10.1016/j.ajpath.2018.04.007The muscle-specific ubiquitin ligase atrogin-1 (MAFbx) has been identified as a critical regulator of
pathologic and physiological cardiac hypertrophy; it regulates these processes by ubiquitinating
transcription factors [nuclear factor of activated T-cells and forkhead box O (FoxO) 1/3]. However,
the role of atrogin-1 in regulating transcription factors in aging has not previously been described.
Atrogin-1 cardiomyocyte-specific transgenic (Tgþ) adult mice (a-major histocompatibility complex
promoter driven) have normal cardiac function and size. Herein, we demonstrate that 18-month-old
atrogin-1 Tgþ hearts exhibit significantly increased anterior wall thickness without functional
impairment versus wild-type mice. Histologic analysis at 18 months revealed atrogin-1 Tgþ mice had
significantly less fibrosis and significantly greater nuclei and cardiomyocyte cross-sectional analysis.
Furthermore, by real-time quantitative PCR, atrogin-1 Tgþ had increased Col 6a4, 6a5, 6a6, matrix
metalloproteinase 8 (Mmp8), and Mmp9 mRNA, suggesting a role for atrogin-1 in regulating collagen
deposits and MMP-8 and MMP-9. Because atrogin-1 Tgþ mice exhibited significantly less collagen
deposition and protein levels, enhanced Mmp8 and Mmp9 mRNA may offer one mechanism by which
collagen levels are kept in check in the aged atrogin-1 Tgþ heart. In addition, atrogin-1 Tgþ hearts
showed enhanced FoxO1/3 activity. The present study shows a novel link between atrogin-1e
mediated regulation of FoxO1/3 activity and reduced collagen deposition and fibrosis in the aged
heart. Therefore, targeting FoxO1/3 activity via the muscle-specific atrogin-1 ubiquitin ligase may
offer a muscle-specific method to modulate aging-related cardiac fibrosis. (Am J Pathol 2018, 188:
1676e1692; https://doi.org/10.1016/j.ajpath.2018.04.007)Supported by the Jefferson-Pilot Corporation Fellowship in Academic
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changes that occur within a lifetime. The capability to
maintain those changes to a minimum is conferred in the
symbiosis between our intrinsic and extrinsic milieu. There
are many physiological processes in humans that evidence
potential for pitfalls in a time-dependent manner and that
could benefit from a much-needed leverage in the process of
aging. There is normal deterioration in many systems, as
evidenced in decrease of cardiac function and tissueregeneration as life progresses.1 Potential instigators, like
diabetes, dyslipidemia, and hypertension, may accelerate the
cardiac aging process and disrupt homeostasis and func-
tionality.2 Such processes of homeostasis are maintained by 
targeted degradation via the ubiquitin proteasome system.
The muscle-specific ubiquitin ligase atrogin-1 (encoded 
by the gene FBXO32) decreases with age in the heart 
(GSE112913), quadriceps,4 and vastus lateralis muscle5 in 
mice and humans. Atrogin-1 (Fbxo32 or MAFbx) plays 
protective role in the pathophysiology of common heart 
diseases.6,7 Atrogin-1 interacts with several components 
to form the S-phase kinase associated protein (Skp) 1/Cullin 
1/F-box protein complex, which conjugates ubiquitin onto 
specific proteins for targeted degradation. Atrogin1 is upre-
gulated in skeletal muscle atrophy and cachectic syn-
dromes.8,9 Denervation and dexamethasone have been 
proved to influence distinctive ubiquitin proteasome system 
gene activity and post-translational modifications in atrophy 
models, specifically of the forkhead box O (FoxO) tran-
scription factors.10,11 Because the FoxO transcription factors 
and atrogin-1 both play a major role in muscle cell atrophy 
and hypertrophy, they hold important therapeutic potential to 
modulate a variety of gene programs.12e16
Recently, stressdinduced either physiologically or 
pathologicallydhas been shown to result in adaptations that 
link the autophagy-lysosome system and the ubiquitin pro-
teasome system, for which atrogin-1 mediation is associ-
ated.17,18 Different substrates for atrogin-1 have been 
identified to have a role in muscle differentiation, contrac-
tility, and hypertrophy. Charged multivesicular body protein 
2B (CHMP2B), part of the endosomal sorting complex, has 
an important role in myocardial interstitial remodeling and 
development of diastolic dysfunction.17 As well, compo-
nents of the extracellular matrix (ECM), like matrix metal-
loproteinase (MMP)-9, may serve as an age-dependent 
regulator of cardiac aging via alteration of ECM collagen 
deposit, which has been shown to occur in humans.19 The 
increased activity of MMP-9 is associated with elevated risk 
for cardiac-associated mortality because of cardiac fibrosis 
development.20 Although the ubiquitin proteasome system 
may regulate such remodeling processes, there is also a 
parallel increase in inflammatory cells that regulate ECM 
activity and are a function of age.21 One of the most 
important cellular components in cardiac tissues are fibro-
blasts, which are identified as targets for treating age-
dependent cardiomyopathies.19,22,23 We hypothesized that 
chronic cardiac-specific overexpression of atrogin-1 would 
regulate age-dependent changes in fibrosis, cell size/num-
ber, and cardiac function.
Materials and Methods
Animals
Adult cardiomyocyte-specific (constitutive a-major histo-
compatibility complex promoter) atrogin-1 transgenic (Tgþ) 
mice, aged 4 to 18 months, were used throughout this study, 
as previously described.24 Mice were subject to a light/darkcycle of 12 hours and had access to water and standard
chow ad libitum (Harlan Laboratories, Inc., Indianapolis,
IN). All animal studies were approved by the Institutional
Care and Use Committee for animal research at the Uni-
versity of North Carolina at Chapel Hill.
Echocardiographic Analysis
High-resolution transthoracic echocardiography was per-
formed on loosely restrained conscious atrogin-1 Tgþ and
litter-matched wild-type mice to phenotypically charac-
terize them at 4, 6, 12, and 18 months using a Vevo 2100
Biomicroscopy system (VisualSonics, Inc., Toronto, ON,
Canada), as previously described.25,26 Briefly, two-
dimensional guided M-mode echocardiography analysis
of the left ventricle was performed in the parasternal long
axis at the level of the papillary muscle. Distances from the
edges of the epicardium and endocardium were used to
measure anterior wall thickness (interventricular septal wall
thickness, end diastolic, and interventricular septal wall
thickness, end systolic), posterior wall thickness (posterior
wall thickness in diastole and posterior wall thickness in
systole), and left ventricular internal diameters [left ven-
tricular end-diastolic dimension (LVEDD) and left ven-
tricular end-systolic dimension (LVESD)]. LV volume in
diastole (LV VolD) was calculated as follows: [LV VolD:
(7/2.4 þ LVEDD)  LVEDD3  1000]. LV volume in
systole (LV VolS) was calculated as follows: [LV VolS: (7/
2.4 þ LVESD)  LVESD3  1000]. Left ventricular
systolic function was assessed by ejection fraction, [Ejec-
tion Fraction %: (LV VolD-LV VolS)/LV VolD  100],
and fractional shortening, [Fractional Shortening %:
(LVEDD/LVESD)/LVEDD  100].
M-mode measurements represent the average of three
consecutive cardiac cycles from each mouse, as previously
described.25,26 Data were analyzed and normalized to
tibia length while blinded to mouse genotype (T.L.P.,
M.S.W.).
Western Immunoblot Analysis of Protein
Frozen heart ventricles from atrogin-1 Tgþ and wild-type
mice were homogenized in SDS lysis buffer (10% SDS,
10 mmol/L tris with pH 7.5, 10 mmol/L NaF, 5 mmol/L
dithiothreitol, and 2 mmol/L EGTA) supplemented with
protease and phosphatase inhibitors (5870S; Cell Signaling
Technology, Danvers, MA) using an electric homogenizer
pulsed five times for 20 seconds at a high speed. Lysates
were boiled for 3 minutes and centrifuged at 13,400  g for
20 minutes at 4C. Lysates were precipitated using chloro-
form/method (using a methanol/chloroform/water mixture
consistent of a 4:1:3 ratio, respectively), as previously
described,27 and the resulting aggregates were solubilized in
NuPAGE LDS Sample Buffer (NP0007; Thermo Fisher
Scientific, Waltham, MA). Protein concentrations were
determined using Pierce 660-nm protein assay (22660;














AWTD, mm (P < 0.001) 0.97  0.11 1.05  0.02 1.02  0.03
AWTS, mm (P < 0.001) 1.64  0.10 1.70  0.05y 1.91  0.03
PWTD, mm (P < 0.001) 0.94  0.10yz 1.10  0.03y 1.26  0.13
PWTS, mm (P Z 0.011) 1.60  0.15 1.78  0.07 1.94  0.10
LVEDD, mm (P < 0.001) 3.37  0.25 3.23  0.12 3.71  0.19
LVESD, mm (P Z 0.021) 1.55  0.19 1.49  0.13 1.67  0.11
LV volume: diastole, mL (P < 0.001) 47.2  8.4 42.6  4.1 59.0  7.1
LV volume: systole, mL 7.0  2.0 6.7  1.8 8.2  1.3
EF, % 85.7  2.3 85.7  2.1 86.2  1.3
FS, % 54.2  2.8 54.3  2.3 54.9  1.5
LV mass index, mg (P < 0.001) 114.0  5.7 130.0  7.0 175.4  25.5
LV mass index/body weight, mg/g 3.6  0.2 4.3  0.3 4.7  0.9
LV mass index/tibia length, mg/mm** 7.0  NA (n Z 1) 7.1  0.3 (n Z 6) 12.3  NA (n Z 1)
Body weight, g 38.4  2.6 31.1  2.2 38.4  2.7
Tibia lengths, mm ND ND ND
Heart rate, bpm 669  48 622  22 667  10
(table continues)
Data are expressed as means  SEM. A one-way analysis of variance was performed (P < 0.05), followed by an all-pairwise multiple comparison procedure
(Holm-Sidak method) to compare means of groups with all other groups.
*P < 0.05 versus all other groups.
yP < 0.05 versus atrogin-1 Tgþ at 18 months.
zP < 0.05 versus atrogin-1 Tgþ at 12 months.
xP < 0.05 versus wild type at 4 months.
{P < 0.05 versus atrogin-1 Tgþ at 4 months.
kP < 0.05 versus atrogin-1 Tgþ at 6 months.
**LV mass (index) Z [1.055 * ((ExLVD;d)3  (LVEDD;d)3)]. Eighteen-month tibia lengths used throughout for normalization.
AWTD, anterior wall thickness in diastole; AWTS, anterior wall thickness in systole; bpm, beats/minute; EF, ejection fraction [calculated
as (end Simpson’s diastolic volume e end Simpson’s systolic volume)/end Simpson’s diastolic volume * 100]; ExLVD, external left ventricle
dimension; FS, fractional shortening [calculated as (LVEDD-LVESD)/LVEDD  100]; LV, left ventricular; LVEDD, LV end-diastolic dimension;
LVESD, LV end-systolic dimension; NA, not applicable; ND, not determined; PWTD, posterior wall thickness in diastole; PWTS, posterior wall
thickness in systole.Thermo Fisher Scientific). For immunoblot, 20 mg of sample
was resolved with NuPAGE Reducing Agent (NP0004;
Thermo Fisher Scientific) and incubated at 65C for 10
minutes. Then, sample was separated by 4% to 12%
SDS-PAGE gel (NP0322; Thermo Fisher Scientific) at
200V in 3-(N-morpholino)propanesulfonic acid (MOPS)
SDS running buffer (NP0001; Thermo Fisher Scientific) for
cardiac myosin binding protein C (cMyBP-C), c-myc,
glucocorticoid receptor (GR), phosphorylated FoxO1/3a,
total FoxO1, and total FoxO3a or 2-(N-morpholino)etha-
nesulfonic acid (MES) SDS running buffer (NP0002;
Thermo Fisher Scientific) for vimentin, CHMP2B, calci-
neurin A, myogenic differentiation 1 (MyoD), muscle ringer
finger-1 (MuRF1), and atrogin-1. Protein was then trans-
ferred onto polyvinylidene difluoride membrane using
NuPAGE transfer buffer with 20% methanol (NP0006;
Thermo Fisher Scientific). The polyvinylidene difluoride
membrane was blocked with 5% dry milk in tris-buffered
saline with Tween 20 for 1 hour at room temperature and
incubated at 4C overnight with the primary antibody.Primary Antibodies
Primary antibodies included the following: antieatrogin-1 (sc-
166806; 1:500 in5%milk;mouse; SantaCruzBiotechnologies,
Dallas, TX); antiecalcineurin Aa (07-1492; rabbit; 1:1000;
EMD Millipore, Burlington, MA), anti-CHMP2B (ABC292;
rabbit; 1:800; EMDMillipore), peroxidase-conjugated antiec-
myc (A5598; rabbit; 1:5000; Sigma-Aldrich, St. Louis, MO),
anti-FoxO1 (2880; rabbit; 1:250; Cell Signaling Technology),
anti-FoxO3a (2497; rabbit; 1:250; Cell Signaling Technology),
antiephosphorylated FoxO1/3a (9464; rabbit; 1:500; Cell
Signaling Technology), antieglyceraldehyde-3-phosphate
dehydrogenase antibody (G8795; mouse; 1:4000; Sigma-
Aldrich), antieglucocorticoid receptor (sc-8992; rabbit;
1:500; Santa Cruz Biotechnology, Inc.), anti-MuRF1 (sc-
27642; goat; 1:200; Santa Cruz Biotechnologies), anti-cMyBP-
C (AXL-215-057-R050; rabbit; 1:5000; Enzo Life Sciences,
Farmingdale, NY), anti-MyoD (ab64159; rabbit; 1:500;
Abcam, Cambridge, MA), anti-vimentin (ab92547; rabbit;




















1.03  0.04 1.05  0.03 1.20  0.03 1.10  0.02 1.40  0.06*
1.72  0.06y 1.82  0.04y 1.91  0.03 1.91  0.03 2.07  0.04
1.09  0.03yz 1.05  0.03yz 1.28  0.05 1.15  0.04y 1.38  0.03
1.78  0.03 1.90  0.06 1.98  0.05 1.96  0.09 2.08  0.07x
3.38  0.15 3.96  0.06yx{ 3.53  0.11 3.93  0.11yx 3.37  0.14
1.55  0.11 1.88  0.04 1.64  0.05 1.81  0.04 1.58  0.10
47.8  4.9 68.8  2.4y{k 52.8  3.7 67.8  4.8y{k 47.7  4.6
7.0  1.2 10.9  0.7 7.8  0.7 10.0  0.6 7.5  1.2
85.9  1.4 84.2  0.5 85.2  0.7 84.8  1.0 84.7  1.70
54.6  1.8 52.7  0.6 53.5  1.0 53.6  1.3 53.2  1.9
134.9  8.2 170.1  7.9x{ 183.1  7.2x{k 185.4  8.6x{k 204.7  10.3x{k
3.7  0.2 3.5  0.2 3.8  0.2 3.7  0.2 4.2  0.3
7.8  0.9 (n Z 6) 9.8  0.8 9.9  0.5 9.9  0.6 11.6  0.6{k
37.0  2.6 49.7  2.4x{k 48.7  2.5xk 51.4  2.3x{k 50.9  3.4x{k
ND ND ND 18  0.3 17.8  0.3
668  10 567  20 584  26 599  24 609  21Abcam), antietissue inhibitor of metalloproteases-1 (TIMP-1; 
Ab38978; rabbit; 1:1000; Abcam), antieTIMP-2 (Ab1828; 
mouse; 1:1000; Abcam), antieTIMP-3 (710404; rabbit; 6 mg/
uL; Thermo Fisher Scientific), and anti-puromycin (MABE343; 
mouse; 1:10,000; EMD Millipore). The membranes were 
washed 3 for 10 minutes in tris-buffered saline with Tween 
20, and secondary antibody was incubated in 5% dry milk in 
tris-buffered saline with Tween 20 for 1 hour at room 
temperature.
Secondary Antibodies
Secondary antibodies included the following: horseradish 
peroxidaseeanti-goat (sc-2768; 1:10,000; Santa Cruz 
Biotechnology, Inc.), horseradish peroxidaseeanti-mouse 
(A9917; 1:10,000; Sigma-Aldrich), and horseradish perox-
idaseeanti-rabbit (A9169; 1:15,000; Sigma-Aldrich). Mouse 
monoclonal antieglyceraldehyde-3-phosphate dehydrogenase 
antibody (G8795; 1:4000; Sigma-Aldrich) or mouse antieb-
actin (A2228; 1:1000; Sigma-Aldrich) was used for our 
loading control and used for normalization for the densitometry 
analysis. Membranes were then washed with tris-buffered sa-
line with Tween 20 for 10 minutes (3), followed by the 
application of ECLþ Plus (RPN2132; GE Healthcare Life 
Sciences, Pittsburg, PA). The electrochemiluminescence 
signal was then visualized for densitometry analysis performed 
on a UVP Bioimaging System with VisionWorksLS software 
version 6.1 (Ultra-Violet Products Ltd, Upland, CA). Regions 
of interest were selected using the rectangular image tool, and 
the background was defined for analysis (R.M.). Both the 
target proteins of interests and glyceraldehyde-3-phosphate 
dehydrogenase were detected within an optimized linear dy-
namic range; the limits of the UVP Bioimaging System have 
standardized lower/upper limits of quantitation. Images 
werepreviewed with exposure compensation while optimizing the
exposure and determining the appropriate final exposure set-
tings. Analyzed images were obtained by exposures from 30
seconds up to 3.5 minutes at 2  2 binning.
qPCR Analysis of Gene Expression
Total RNA was isolated from atrogin-1 Tgþ and wild-type
ventricles using Trizol, according to manufacturer’s in-
structions (15596026; Ambion by Life Technologies, Carls-
bad, CA) and resuspended in RNAse-free water. Real-time
quantitative PCR (qPCR) analysis was then performed using a
two-step reaction. cDNA was first made using the High Ca-
pacity cDNA Archive kit (Applied Biosystems, Foster City,
CA), then quantified in a second reaction, described below.
Quantification Using TaqMan Probes
One microliter of cDNA product was then amplified using
0.6 mL of TaqMan probes and TaqMan Universal PCR
Master Mix (final volume, 12 mL). The exon-spanning Taq-
Man probes included the following: Anf (Mm01255747_g1),
Bnp (Mm00435304_g1), Acta1 (Mm00808218_g1), Myh7
(myosin, heavy chain 7, cardiac muscle, b; Mm00600555_
m1), Nr3c1 (Mm00433832_m1), Ryr (Mm00465877_m1),
Ptgds (Mm01330613_m1), Dmd (Mm01216951_m1), Timp3
(Mm00441826_m1), and Klf15 (Mm00517792_m1). The 18S
TaqMan probe (Hs99999901_s1) was used as a reference gene.
SYBR Green Quantification
Each reaction consisted of cDNA, 2 Power SYBR Green
Master mix, or 2 QuantiNova SYBR Green Master mix,
primers (for Power SYBR green reactions, 200 nm; for
QuantiNova SYBR green, 0.7 mmol/L), and RNase-free water.
Relative mRNA expression was determined using 18S as a
loading control. The following primers were designed to detect
exon spanning collagen and MMP mRNAs, as follows:
Col1a1, 50-GAGCGGAGAGTACTGGATCG-30 (forward)
and 50-GCTTCTTTTCCTTGGGGTTC-30 (reverse); Col6a1,
50-TGCCCTGTGGATCTATTCTTCG-30 (forward) and 50-
CTGTCTCTCAGGTTGTCAATG-30 (reverse); Col6a2, 50-
TGCCCTGTGGATCTATTCTTCG-30 (forward) and 50-
CTGTCTCTCAGGTTGTCAATG-30 (reverse); Col6a3, 50-
AACCCTCCACATACTGCTAATTC-30 (forward) and 50-
TCGTTGTCACTGGCTTCATT-30 (reverse); Col6a4, 50-
ATGACAAGTGCCGACCAGCC-30 (forward) and 50-
ACTAGCCGCAAAGCCCCAAG-30 (reverse); Col6a5, 50-
TGCTCTGTTGGTGGTGTCCC-30 (forward) and 50-
TGCCCAGGTCTAGCATCCCA-30 (reverse); Col6a6, 50-
TTCAGTGCACAGAGGGGCAG-30 (forward) and 50-
ACAGCTGCCTTGGTCACGT-30 (reverse); Mmp8, 50-
TCAACCAGGCCAAGGTATTG-30 (forward) and 50-
ATGAGCAGCCACGAGAAATAG-30 (reverse); Mmp9, 50-
TTGGTTTCTGCCCTAGTGAGAGA-30 (forward) and 50-
AAAGATGAACGGGAACACACAGG-30 (reverse);
Mmp12, 50-TGACATACGTAACATTCAGTCCC-30 (for-
ward) and 50-TCTCTCCCACTGTTGTGACAG-30 (reverse);
Timp1, 50-CCCTTCGCATGGACATTTATTC-30 (forward)
and 50-TCTGCTCTGGTGTGTCTCTA-30 (reverse); Timp2,
50-ACATCGAGGACCCGTAAGA-30 (forward) and 50-
TTCCAGGAAGGGATGTCAAAG-30 (reverse); and 18S, 50-
AGAAACGGCTACCACATCCA-30 (forward) and 50-
CTCGAAAGAGTCCTGTATTGT-30 (reverse). All reactions
were run in a LightCycler 480 II System (04707494001; Roche,
Basel, Switzerland) and quantified by the LightCycler 480
Software version 1.5.0 SP4 (Roche). Power SYBR Green PCR
genemelting curveswere performed for each reaction to ensure a
single productwasdetected in each reaction.Raw threshold cycle
(CT) values were analyzed using the DDCT method, where CT
values were first normalized to 18S. Fold change values (calcu-
lated by the formula 2DDCT ) were used as final expression data.
Cardiac Perfusion and Histologic Preparation
Eighteen-montheold mice were euthanized using isoflurane
(open-drop method)28 and secondary cervical dislocation,
followed by gravity perfusion with 4% paraformaldehyde,
fixed for 24 hours, followed by storage in 75% ethanol.
Fixed cardiac tissue was processed for paraffin embedding,
sectioned, and stained with standard hematoxylin and eosin
(H&E) and Masson’s trichrome (MT) staining. Additional
slides were cut and used for immunofluorescence studies.
Stained slides were scanned on a Leica Aperio VERSA
ScanScope XT epifluorescent microscope digital scanner
(DM6000 B; Leica Biosystems Inc., Buffalo Grove, IL) at
20 with an Andor Zyla sCMOS camera and were visual-
ized/analyzed using Aperio ImageScope version
12.1.0.5029 (Aperio Technologies Inc., Vista, CA),
including export of TIFF images used in publication (R.M.).Algorithmic Analysis of Collagen and Cross-Sectional
Area Analysis of Masson’s TrichromeeStained Slides
Scanned MT-stained slides were analyzed in Aperio
ImageScope using the Aperio positive pixel v9 algorithm
using standard parameter settings (hue value Z 0.66; hue
width Z 0.45 to 0.55 set and confirmed visually using the
markup feature for each slide). The amount of collagen was
determined as a percentage of tissue. Three biological rep-
licates (each with three sections) were analyzed per geno-
type. MT-stained slides were analyzed for cardiomyocyte
cross-sectional area quantification, as previously
described.25 Briefly, ventricular sections were visualized
using the Aperio ImageScope version 12.1.0.5029 (Aperio
Technologies) and exported as TIFF files with scale bars (at
20 magnification). Cardiomyocyte length was quantified
in a blinded manner (R.M.) using ImageJ software version
1.51 (NIH, Bethesda, MD; http://imagej.nih.gov/ij) across
four to six histologic sections per mouse from a total of
three hearts per genotype, analyzing 100 cells per heart.
Data represent mean cardiomyocyte length (mm).
Algorithmic Analysis of Total Nuclei in H&E-Stained
Cardiac Sections
Nuclear quantification analysis was performed on H&E-
stained slides with Definiens Architect 2.7 Build 59337
(Biocompare, San Francisco, CA) using the Tissue Studio
version 4.4.1 portal. The images were first imported into the
application along with their respective ventricular tissue
annotations. Each tissue section was independently
analyzed, and the output was parsed accordingly. The re-
gions of interest were further segmented into tissue and
glass regions, with only the tissue class being analyzed for
nuclear detection. The results included Analyzed Tissue
Area, Total Nuclei, and Nuclear Density on the basis of the
nuclear size values. The H-score was calculated as follows:
H-Score: (3  % Nucleus Large) þ (2  % Nucleus
Medium) þ (1  % Nucleus Small).
The analysis output included all quantitative results as
well as color-coded overlays that represented the stained
nuclei. Data are represented as sum of nuclei density (n/
mm2) and total nuclei/area (mm2) normalized to analyzed
tissue area. Analysis was performed in a blinded manner
(B.M.; University of North Carolina Tissue Pathology
Laboratory core facility). A secondary nuclear quantification
analysis was performed using the Aperio ImageScope sys-
tem in the user-defined regions of interests in the ventricular
tissue and analyzed with the Aperio Nuclear v9 algorithm
configured as a custom macro for this assay. To generate a
customized analysis macro with the Aperio Nuclear v9 al-
gorithm, the principal colors of the H&E stain were sampled
to obtain representative OD values for the redegreeneblue
color space. These values were used as inputs to mark the
appropriate stains. Other input parameters (eg, minimum
































































































































Figure 1 Conscious echocardiographic analysis of aging atrogin-1 Tgþ hearts. A and B: High-resolution transthoracic echocardiography measurements of
atrogin-1 Tgþ and litter-matched wild-type mouse hearts identified significant alterations in the anterior wall thickness at 4, 6, 12, and 18 months of age (A)
and left ventricular volume (LV Vol) in diastole (B). C: Four-chamber view of representative wild-type and atrogin-1 Tgþ hearts at 18 months of age. D:
Representative M mode of atrogin-1 Tgþ hearts at 4, 12, and 18 months of age. E: Heart weight at 18 months of age at harvest and heart weight at 18 months
of age at harvest normalized to tibia length. A one-way analysis of variance was performed, followed by an all-pairwise multiple comparison procedure (Holm-
Sidak method) to compare means of groups with all other groups. A t-test was performed. Red: left ventricular wall thickness in diastole. Yellow: left ven-
tricular wall thickness in systole. Data are expressed as means  SEM (A, B, and E). *P < 0.05 versus all other groups (analysis of variance); yP < 0.05 versus
atrogin-1 Tgþ at 18 months (analysis of variance); zP < 0.05 versus atrogin-1 Tgþ at 4 months (analysis of variance); xP < 0.05 versus atrogin-1 Tgþ at 12




















































































































































































































































adjusted to achieve nuclear segmentation. Data represent
nuclei/mm2. Histologic analysis was performed in a blinded
manner (R.M. and B.M.; University of North Carolina
Tissue Pathology Laboratory core facility).
Immunofluorescence Staining of Cardiac Histologic
Sections for Vimentin and Collagen I
Immunostaining was performed as described previously.25
Briefly, cardiac sections were stained with antibodies against
the following: anti-vimentin (ab137321; 1:500; Abcam),
antiecollagen I (ab34710; 1:100; Abcam), and rabbit IgG (as a
negative control) at 4C overnight. Sections were then treated
with Alexa Fluor 488econjugated or Alexa Fluor
594econjugated secondary antibodies and counterstainedwith
DAPI. Total positive vimentin stained cells were identified and
counted in each of the four cross-sectional defined areas using
Meta-Morph software version 7.8 (Molecular Devices, San
Jose, CA). Images were taken using Axio Imager 2 (Carl Zeiss
Microscopy, LLC, Thornwood, NY).
Protein Synthesis
The surface sensing of translation (SUnSET) technique was
used to determine protein synthesis in 6-montheold atrogin1
Tgþ (nZ 5) and litter-matched wild-type (nZ 4)mice and in
16-montheold atrogin1 Tgþ (nZ 2) and litter-matched wild-
type (n Z 2) mice, as previously described.29 Briefly, mice
were injected intraperitoneally with 0.04 mmol/L puromycin
dihydrochloride (61-385-RA; Corning Inc., Corning, NY)
diluted in phosphate-buffered saline 30 minutes before har-
vest. Hearts were harvested andflash frozen in liquid nitrogen.
Heart lysates were prepared and blotted for puromycin
(MABE343; mouse; 1:10,000; EMDMillipore), as described
earlier in Western Immunoblot Analysis of Protein. Total
protein levels were assessed by staining the membrane with
Ponceau S stain (7170; Sigma-Aldrich) for 5 minutes.
Serum Chemistry
Blood was collected from 13- to 18-montheold atrogin1
Tgþ (n Z 8) and litter-matched wild-type (n Z 3) mice via
submandibular bleed, and serum was collected via serum
separator tubes (365978; BD Microtainer; Becton Dick-
inson, Franklin Lakes, NJ). Serum was next analyzed forFigure 2 Histologic analysis of perfused atrogin-1 Tgþ and litter-matchedwild-t
atrogin-1 Tgþ hearts at 18 months of age using an algorithm-based determination
performed in a total of three histologic sections per mouse heart (three biological re
three biological replicate assays in three left ventricular cross sections with repre
montheold atrogin-1 Tgþ ventricles for skeletal muscle actin (Acta1), b-major his
pathologic cardiac hypertrophy. D: Representative hematoxylin and eosinestained h
(number per area) and total nuclei per section in atrogin-1 Tgþ hearts using Defini
sections per mouse heart (three biological replicates per genotype). F: Histologic ana
(number per area) and total nuclei per section in atrogin-1 Tgþ hearts usingAperio so
per mouse heart (three biological replicates per genotype). A two-tailed t-test was
means  SEM (AeC, E, and F). nZ 3 biological replicates per group (C). *P < 0.0alanine aminotransferase (SA1046; Alfa Wassermann
Diagnostic Technologies, LLC, Caldwell, NJ), alkaline
phosphatase (RX2002; Alfa Wassermann Diagnostic
Technologies, LLC), blood urea nitrogen (SA2024; Alfa
Wassermann Diagnostic Technologies, LLC), and creatinine
(SA1012; Alfa Wassermann Diagnostic Technologies,
LLC) via Ace Axcel clinical chemistry system (Alfa Was-
sermann Diagnostic Technologies, LLC) by the University
of North Carolina Clinical Chemistry laboratory.
Cell Culture, Adenoviral Transduction
HL-1 cells were maintained, as published previously.30
Tissue culture dish was coated with a mixture of 0.02%
gelatin (w/v)e0.5% fibronectin (v/v) for 60 minutes. Cells
were trypsinized (0.05% trypsin þ EDTA) and seeded in 6-
well dishes to adhere overnight in Claycomb medium
(Sigma-Aldrich) supplemented with 10% fetal bovine
serum, 1% penicillin-streptomycin, 1% norepinephrine,
and 1% L-glutamine. After culturing for at least 24 hours,
medium was changed and cells were transduced with
increasing multiplicities of infection of a bicistronic
adenovirus construct expressing myceatrogin-1 [Ad-
Atrogin-1-green fluorescence protein (GFP)] or GFP con-
trol (Ad-GFP), as previously described.24,30 Twenty-four
hours after plating, cells were transfected at different
multiplicities of infection (0, 10, 20, 50, 100, and 200) in
triplicate with both Ad-Atrogin-1-GFP and Ad-GFP for 24
to 48 hours. Fluorescence microscopy imaging was per-
formed on an Eclipse TS100 microscope (Nikon, Inc.,
Melville, NY) with a QIClick camera (model 74-0083-A0;
QImaging, Surrey, British Columbia, Canada) to verify
presence of increased GFP and GFP-Atrogin-1 trans-
duction in HL-1 cells as multiplicity of infection increased.
Post-transduction cells were harvested for protein using
radioimmunoprecipitation assay buffer [10 mmol/L tris-Cl
(pH 8.0), 1 mmol/L EDTA, 0.5 mmol/L EGTA, 1% Triton
X-100, 0.1% sodium deoxycholate, 0.1% SDS, and 140
mmol/L NaCl] in the presence of protease and phosphatase
inhibitors (5870S; Cell Signaling Technology).
Statistical Analysis
Statistics were computed by either a two-tailed t-test when
comparing means from two groups or a one-way analysis ofype hearts at 18months of age.A:Determination of thepercentage collagen in
of collagen with representative low-power images. Histologic analysis was
plicates per genotype). B: Cardiomyocyte cross-sectional area determined on
sentative low-power images. C: Real-time quantitative PCR analysis of 18-
tocompatibility complex (MHC; Myh7), Anf, and Bnp mRNA associated with
istologic sections of atrogin-1 Tgþ hearts. E: Quantification of nuclei density
ens software. Histologic analysis was performed in a total of three histologic
lysis of nuclei number using Aperio software. Quantification of nuclei density
ftware. Histologic analysis was performed in a total of three histologic sections
performed to determine significance between groups. Data are expressed as
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Figure 3 Analysis of atrogin-1 Tgþ cardiac fibroblasts by vimentin immunofluorescence analysis. A: Atrogin-1 fibroblast areas in a perivenular distribution
were accessed for (vimentin-positive) cells colocalized by immunohistochemistry in four quadrants (Q1eQ4) as oriented to the right and left ventricles (RV and
LV). B: Nonbias quantitative logarithmic analysis of vimentin (þ) cell staining in quadrants 1 to 4 by immunofluorescence microscopy of 18-montheold
atrogin-1 Tgþ hearts. Representative immunofluorescence images can be found in Supplemental Figure S2. C: Whole section vimentin-positive fibroblast area
(Q1eQ4). D: Vimentin immunoblots (IBs) of atrogin-1 Tgþ heart lysate. A two-tailed t-test was performed to determine significance between groups. Data are
expressed as means  SEM (BeD). n Z 3 biological replicates per group (B); n Z 4 per group (D). *P < 0.05, **P < 0.01 versus age-matched wild-type
controls. AU, arbitrary unit; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.variance to compare means from multiple groups. If the one-
way analysis of variance was significant, a subsequent all-
pairwise multiple comparison procedure (Holm-Sidak
method) was then performed to compare all of the groups
with each other in a pairwise manner. P  0.05 was
considered significant. GraphPad Prism 7.0 (GraphPad
Software, Inc., La Jolla, CA) was used for all statistical
analyses, except echocardiography, which used Microsoft
Excel 2016 (Microsoft, Redmond, WA) and SigmaPlot
version 11.0 build 11.0.0.77 (Systat Software, Inc., San
Jose, CA). Data represent means  SEM, unless otherwise
noted.Results
Cardiomyocyte-specific atrogin-1 Tgþ mice were analyzed
for cardiac function longitudinally to 18 months of age by
conscious echocardiography. The atrogin-1 Tgþ hearts do
not significantly differ from litter-matched wild-type mice at
4 or 6 months of age by conscious echocardiography
(Table 1), as previously described in 12-weekeold atrogin-1
Tgþ mice.31 Significantly increased anterior wall thicknesswas seen in atrogin-1 Tgþ hearts at 18 months of age
(Figure 1A), as was significantly decreased LV volume
in diastole (Figure 1B). Significant increases in the left
ventricular posterior wall in diastole were also seen in
the atrogin-1 Tgþ hearts (1.38  0.03 mm) compared with
litter-matched wild-type mice (1.15  0.04 mm) (Table 1).
Representative M-mode images illustrate the atrogin-1
Tgþ increased anterior and posterior wall thickness at 18
months, increased anterior wall thickness in diastole, and
increased posterior wall in systole in the atrgoin-1
Tgþ anterior wall (Figure 1D). On low-power analysis,
the atrogin-1 Tgþ hearts did not grossly appear different
(Figure 1C), whereas the measured atrogin-1 Tgþ heart
weights at harvest were significantly decreased with and
without normalization to tibia length at 18 months of age
(Figure 1E). No changes in systolic function were identified
in the atrogin-1 Tgþ hearts (ie, ejection fraction and frac-
tional shortening) throughout the course of the study
(Table 1), consistent with previous studies of no functional
changes for up to 8 months of age.24,31
Age-related changes in cardiac homeostasis are observed
in the heart. The hallmarks of these changes are progressive
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Figure 4 Real-time quantitative
PCR analysis of extracellular matrix
genes in 18-montheold atrogin-1
Tgþ hearts. Quantitative analysis of
ventricular collagen 1 (Col1; A),
collagen 6a-1 (Col6a1; B), collagen
6a-2 (Col6a2; C), collagen 6a-3
(Col6a3; D), collagen 6a-4 (Col6a4;
E), collagen 6a-5 (Col6a5; F),
collagen 6a-6 (Col6a6; G), matrix
metalloproteinase 8 (Mmp8; H),
matrix metalloproteinase 9 (Mmp9;
I), matrix metalloproteinase 12
Mmp12; J), tissue inhibitor of met-
alloproteinase 1 (Timp1; K), tissue
inhibitor of metalloproteinase 2
(Timp2; L), and tissue inhibitor of
metalloproteinase 3 (Timp3; M)
mRNA. A two-tailed t-test was per-
formed to determine significance
between groups. Data are expressed
as means  SEM (AeM). *P < 0.05,
**P < 0.01 versus age-matched wild-
type controls.development of fibrosis.21 Therefore, measures of these 
hallmarks were studied to determine whether the increased 
atrogin-1 in cardiomyocytes affected these aging changes. 
First, the amount of collagen deposition was analyzed byMT-stained histologic sections using a nonbiased logarith-
mic analysis of digitally scanned glass slides. The atrogin-1
Tgþ hearts exhibited significantly less (68.8% less) collagen
deposition (1.45  0.26%) compared with the collagen
Figure 5 Immunofluorescence (IF) staining of collagen 1 in atrogin-1
Tgþ hearts at 18 months of age. Representative collagen 1 staining (red)
with DAPI (blue) counterstaining of atrogin-1 Tgþ hearts versus litter-
matched wild-type hearts. Original magnification, 20.staining consistently seen in the wild-type hearts
(4.68  0.72%) (Figure 2A). Cross-sectional analysis of
atrogin-1 Tgþ hearts was found to be significantly increased
40.1% in cross-sectional area (189.1  19.0 mm2) compared
with age-matched wild-type mice (134  1.7 mm2)
(Figure 2B). To identify if this apparent increase in car-
diomyocyte size (hypertrophy) was a result of pathologic
hypertrophy signaling pathways, skeletal muscle actin,
Myh7, Anf, and Bnp mRNAs were assayed in atrogin-1
Tgþ hearts compared with wild-type hearts, and no differ-
ences were observed by qPCR analysis (Figure 2C). Anal-
ysis of the H&E-stained slides indicated that there might be
an increase in nuclei (Figure 2D), so the slides were
analyzed using two different algorithms (Definiens and
Aperio) that unbiasedly recognized nuclei (Figure 2, E and
F). Analysis of the atrogin-1 Tgþ hearts revealed a signifi-
cant increase in nuclei in LV cross sections normalized to
area using the Definiens (Figure 2E) and Aperio (Figure 2F)
algorithms. Together, these studies illustrate that the
atrogin-1 Tgþ hearts have significantly less fibrosis and an
increase in cardiomyocyte area not related to pathologic
hypertrophy (evidenced by no increase in fetal gene
expression), with an increase in nuclei using a systemic
analysis of the histology.
Cardiac fibroblasts are the major producer of the ECM,
including collagen. The aging effects on cardiac fibroblastsinclude an increase in collagen production and an increase in
fibroblast senescence.32 We, therefore, hypothesized that the
significantly greater atrogin-1 Tgþ nuclei number (Figure 2,
D and F) represented an increase in cardiac fibroblasts.
Immunohistochemistry was performed on atrogin-1
Tgþ hearts for fibroblast-associated vimentin, and the area
was quantified to identify the fibroblast areas in different
regions of the heart (Figure 3, A and B, and Supplemental
Figure S1). There appear to be regional differences in the
atrogin-1 heart fibroblast areas, with significantly less in
quadrant 1 compared with wild-type hearts and significantly
more in quadrant 3 (Figure 3B). Overall, atrogin-1 Tgþ hearts
did not have significantly different fibroblast areas compared
with wild-type hearts (Figure 3C). Immunoblot analysis of
heart lysates similarly found no significant differences in
atrogin-1 Tgþ hearts compared with wild-type controls at 18
months of age (Figure 3D). Together, these findings
demonstrate that atrogin-1 Tgþ hearts have cardiac fibroblast
numbers equivalent to wild-type hearts at 18 months of age.
The significant reduction in atrogin-1 Tgþ heart fibrosis
identified in Figure 2A may be the result of either decreased
collagen 1/3 or increased degradation. Because the collagen
subtypes can contribute significantly to the heart pheno-
type,33 collagen and Mmp mRNA expression was investi-
gated by qPCR. Unexpectedly, atrogin-1 Tgþ hearts did not
have decreased Col1 mRNA (Figure 4A), which is a major
contributor to the MT-stained blue signal in Figure 2A.
Type 6 collagen has been reported to induce cardiac myo-
fibroblast differentiation,34 with the three novel subtypes
(collagen 6a-4, 6a-5, and 6a-6) expressed in fetal tissues.35
Atrogin-1 Tgþ hearts exhibited significant increases in
Col6a4 and Col6a5, whereas no significant differences were
seen in the other subtypes compared with wild-type hearts
(Figure 4, BeG). Furthermore, atrogin-1 Tgþ hearts had
significantly increased Mmp8 and Mmp9 mRNA (Figure 4,
H and I), but not Mmp12 mRNA (Figure 4J). No significant
differences were found in Timp1, Timp2, and Timp3
mRNA levels (Figure 4, KeM). Collagen 1 protein levels
were determined by immunohistochemistry (Figure 5) and
illustrated the significant decrease in collagen 1 in atrogin-1
Tgþ hearts compared with wild-type hearts, where it was
found distributed at much higher levels throughout the tis-
sue (Figure 5). Together, these findings suggest that the
atrogin-1 Tgþ hearts have alterations in collagen 1 degra-
dation, given their significantly decreased collagen 1 protein
with nonsignificant changes in Col1 mRNA. Furthermore,
the identification of significantly increased Col6a4, Col6a5,
Mmp8, and Mmp9 mRNA illustrates altered remodeling of
distinct collagen subtypes, with the collagen 6a subtypes
relatively unknown in the context of the aging heart.
Aging has been associated with a decrease in GR
expression in the heart. Decreases up to 70% in nuclear
receptor subfamily 3 group C member 1 (Nr3c1) mRNA
encoding GR have been reported in old hearts compared
with young hearts (from published data sets: GSE112913













































































































































































































































































Figure 6 Immunoblot analysis of previously reported atrogin-1 substrates (see Results) in atrogin-1 Tgþ hearts at 18 months of age. Densitometric
analysis of atrogin-1 Tgþ heart protein levels of calcium and calmodulin-dependent serine/threonine protein phosphatase calcineurin Aa (A), p-forkhead box
protein O1 (FoxO1)/total FoxO1 (B, left graph), p-forkhead box protein O3 (FoxO3)/FoxO3 (B, right graph), charged multivesicular body protein 2B (CHMP2B;
C), myogenic differentiation 1 (MyoD; D), cardiac myosin binding protein C (cMyBP-C; E), and muscle ring finger-1 (MuRF1; F). All immunoblots (IBs) were
normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). A two-tailed t-test was performed to determine significance between groups. Data are
expressed as means  SEM. n Z 4 per group. *P < 0.05 versus age-matched wild-type controls. AU, arbitrary unit.
results in the development of increased cardiomyocyte
size,37,38 as seen in the atrogin-1 Tgþ hearts. Because GR
degradation occurs in a proteasome-dependent manner39
and the ubiquitin ligase mediating its degradation is
unknown, we hypothesized that atrogin-1 might mediate
this degradation. HL-1 cardiomyocyte-derived cells were
transduced with increasing atrogin-1 using adenovirus (Ad-
Atrogin-1) to identify its effect on steady-state GR.
Increasing atrogin-1 resulted in a decreased GR protein level
at the highest atrogin-1 level (Supplemental Figure S2).
Eighteen-montheold atrogin-1 Tgþ hearts were next
assayed by qPCR for the expression of reported GR-
regulated genes,38 including dystrophin (Dmd ), Kruppel-
like factor 15 (Klf15), ryanodine receptor 2 (Ryr2), GR
(Nr3c1), and prostaglandin D2 synthase (Ptgds)
(Supplemental Figure S3). We identified that atrogin-1
Tgþ did not have any changes in GR activity, as identi-
fied by the expression of these GR-regulated genes
(Supplemental Figure S3). Further assay of atrogin-1
Tgþ hearts for atrogin-1 levels demonstrated a 43.0% in-
crease in atrogin-1 protein (Supplemental Figure S4), which
may explain the lack of effect of apparent GR activity
because much higher atrogin-1 levels (65.3-fold endogenous
levels) were needed to identify an effect on GR protein
levels (Supplemental Figure S2). Together, these findings
ruled out atrogin-1’s effect on GR as a mechanism of the
observed cardiac phenotype in vivo.
The ubiquitin ligase activity of the muscle-specific
atrogin-1 protein has multiple substrates that have been re-
ported as substrates, including calcineurin A,24 FoxO1/3a,31
CHMP2B,17 MyoD,40,41 and cMyBP-C.42 Because these
activities have been described in the context of different
disease states, including pathologic24 and physiological31
cardiac hypertrophy, cardiomyopathies,17,42 and skeletal
muscle atrophy,40,41 their roles in cardiac aging were not
anticipated. Consistent with previous studies demonstrating
that atrogin-1 monoubiquitination preserved calcineurin A
protein levels in pathologic cardiac hypertrophy,24 immu-
noblot analysis revealed that atrogin-1 Tgþ hearts had
significantly increased calcineurin A protein levels at 18
months of age (Figure 6A). Prior studies identified that
increasing atrogin-1 resulted in the interaction and mono-
ubiquitination of FoxO1/FoxO3a substrates, resulting in
increased FoxO1/3a activity in physiological cardiac hy-
pertrophy.31 Consistent with this, decreases were identified
in phosphorylated FoxO1 and phosphorylated FoxO3a
(Figure 6B), which are the protein species excluded from the
nucleus. Recent studies identified CHMP2B as a critical
protein regulating endosomal sorting complex in autophagy,
with atrogin-1/ hearts failing to degrade CHMP2B,
resulting in increased CHMP2B proteins levels.17 On the
basis of these findings, it was anticipated that increased
atrogin-1 in atrogin-1 Tgþ hearts would have significantly
less CHMP2B, resulting from enhanced protein degrada-
tion. However, significantly greater CHMP2B protein levels
were identified by immunoblot (Figure 6C). Anotheratrogin-1 substrate found in skeletal muscle atrophy is
MyoD, which has been reported to be degraded after
atrogin-1 ubiquitination.40,41 However, like CHMP2B,
MyoD levels were not decreased, as expected (Figure 6D).
In fact, atrogin-1 Tgþ heart MyoD protein levels trended
(P Z 0.0752) toward being increased compared with aged
wild-type control hearts (Figure 6D). Limited previous
studies in cardiomyopathies have identified cMyBP-C as an
atrogin-1 substrate targeted for degradation, making it ex-
pected to be decreased in atrogin-1 Tgþ hearts.42 However,
atrogin-1 Tgþ heart cMyBP-C was not significantly
different from wild-type hearts (Figure 6E). Last, it was
investigated if the other muscle-specific ubiquitin ligase
MuRF1 protein expression was affected by increased
atrogin-1, because MuRF1 expression is regulated by
FoxO1/3a in skeletal muscle atrophy,9,43,44 and changes in
MuRF1 expression are altered in specific disease con-
texts.30,45,46 Atrogin-1 Tgþ hearts were not significantly
different from wild-type control hearts at 18 months of age
(Figure 6F). There were no significant differences in protein
synthesis between groups, as evidenced by incorporation of
the amino acid analog puromycin, detected by immunoblot
in 6-montheold atrogin-1 Tgþ hearts (Supplemental
Figure S5A) or in 16-montheold (aged) atrogin-1
Tgþ hearts (Supplemental Figure S5B). No significant dif-
ferences were identified in atrogin-1 Tgþ serum alanine
aminotransferase, alkaline phosphatase, blood urine nitro-
gen, and creatinine (Supplemental Figure S6) compared
with wild-type controls. Overall, it was identified that
atrogin-1 Tgþ hearts had significantly increased calcineurin
A and CHMP2B expression, along with significantly
decreased phospo-FoxO1/FoxO1 and phospo-FoxO3a/
FoxO3a.Discussion
Aging is associated with a decrease in cardiac (GSE112913),
quadriceps,4 and vastus lateralis muscle5 atrogin-1 (encoded
by the gene FBXO32) in mice and humans. Atrogin-1 loss-
of-function mutations have recently been identified as a
cause of dilated cardiomyopathy in human patients,47 and
atrogin-1/ animals exhibited increased fibrosis with
aging, recently identified to be related to the accumulation of
CHMP2B, a purported atrogin-1 substrate, linked to an
observed impaired autophagy.17 In the present study, we
determined how prevention of this age-associated loss of
atrogin-1 in cardiomyocytes may affect the age-related
changes that occur in the heart. Aged atrogin-1 Tgþ hearts
had a significant decrease in cardiac fibrosis by trichrome
staining (Figure 2A) and collagen 1 immunofluorescence
(Figure 5), in the absence of increased collagen 1 mRNA
(Figure 4A). These findings are consistent with an increase in
collagen degradation. Significant increases in Mmp8 and
Mmp9 mRNA (Figure 4, H and I) with no corresponding
increase in Timp1-3 mRNA (Figure 4, KeM) offer one
potential mechanism by which this may occur. MMPs, 
including MMP-8 and MMP-9, are elevated with cardiac 
aging and oversee signaling during the aging process by 
modulating cytokines, chemokines, growth factors, hor-
mones, and angiogenic factor expression and activity.21 
ProeMMP-9 forms a tight complex with TIMP-1 and 
TIMP-3.48 Because all TIMPs are known to interact with 
MMP-9 and inhibit its activity,49 the ratio of MMP-9/TIMPs 
is also critical to the accumulation of collagen and age-
associated fibrosis. Although cardiomyocyte transgenic 
MMP-9 mice have not been generated, to our knowledge, 
macrophage transgenic MMP-9 mice exhibit decreases in 
fibrosis in age-related cardiac changes.50 MMP-8 is a colla-
genase that cleaves interstitial collagens I, II, and III into 
characteristic fragments, while digesting other ECM mole-
cules and proteins.48 These activities may explain why 
elevated MMP-8 has antifibrotic roles in the liver51 and may 
be responsible for the antifibrotic phenotype identified in the 
atrogin-1 aged hearts in the present study.
The FoxO1/FoxO3 transcription factors play a role in aging 
and longevity.52,53 The FoxO1/FoxO3 homolog FoxO 
(encoded by Daf-16) in  Caenorhabditis elegans is pivotal in 
aging, as demonstrated by microarray, proteomics, and DNA 
adenine methyltransferase identification studies.54e57 More 
than 100 ortholog of the FoxO family of transcription factors 
in the nematode Caenorhabditis elegans (DAF-16) direct 
targets were identified,58 with more than a dozen targets 
involved in longevity.52 These targets include ACOnitase, 
glyceraldehyde 3-phosphate dehydrogenase, leucyl amino-
acyl tRNA synthetase, PeRoxireDoXin, and sarcoplasmic-
endoplasmic reticulum calcium ATPase, among others.52 
The ubiquitin proteasome system determines the stability of 
FoxO proteins, the ubiquitin ligases reported to mouse double 
minute 2, SKP2, constitutive photomorphogenesis protein 1, 
and C terminus of Hsp70-interacting protein responsible 
for the ubiquitination and degradation of FoxOs.59e62 
Moreover, phosphorylation of FoxOs by extracellular 
signaleregulated kinase or IkB kinase contributes to FoxO 
degradation.61,63 The arginine methyltransferase protein 
arginine methyltransferase 1 methylates DAF-16/FoxO, 
which can block AKT phosphorylation of DAF-16, result-
ing in longevity and stress tolerance.64 This parallels findings 
in mammalian cell.65 Previous studies by our group have 
found that cardiac atrogin-1 does not mediate ubiquitin-
dependent degradation of FoxO transcription factors.31 In 
contrast, atrogin-1 was found to polyubiquitinate (via K63 
linkages) FoxO and enhance its activity.31 In these studies, 
atrogin-1 was found to inhibit Akt-dependent (physiological) 
cardiac hypertrophy by ubiquitin-dependent coactivation of 
FoxO1/FoxO3 in vivo, including the atrogin-1 Tgþ mouse 
model described in the present study.31 Consistent with these 
findings, the present study identified that increased car-
diomyocyte atrogin-1 enhanced FoxO1/FoxO3a activity in 
aged mice (Figure 6, B and C). Because modest increases in 
FoxO levels have been reported to be cardioprotective in 
age-associated functional declines in Drosophila,66increasing atrogin-1 may be one way to support FoxO1/
FoxO3a activity to protect against age-associated declines in
cardiac function.
Age-related sarcopenia is the decline of muscle mass and
strengthwith age and involves decrease in insulin-like growth
factor-1 (IGF-1) signaling, which is required for maintenance
of muscle mass in the aging process.67 Age-related decreases
in IGF-1 promote phosphatidylinositol 3-kinase, mitogen-
activated protein kinase, and calcineurin pathways, and
exercise and injury induction of IGF-1 protect against
age-related sarcopenia.67 The IGF-1 and the IGF-1 receptor
(IGF-1R) are implicated in cardiac aging and longevity.68 In
the present study, atrogin-1 Tgþ hearts have enhanced
FoxO1/3a transcription factor activities (Figure 6B), which
would predictably inhibit IGF-1 signaling, as previously
described in atrogin-1 Tgþ.31 The observed decreases in
cardiac mass (Figure 1E) likely reflect an enhanced age-
related loss of cardiac muscle (sarcopenia) mediated by
these effects. The significant increase in atrogin-1 Tgþ LV
mass index normalized to tibia length (Table 1) and car-
diomyocyte cross-sectional area (Figure 2B) suggests some
compensatory increases in LVmuscle despite the overall loss
of muscle mass. IGF-1 signaling has important roles in car-
diac aging.68 Deletion of IGF-1R has been shown to delay the
development of senescence-associated pathologies.69 Spe-
cifically, aging is associated with the induction of IGF-1R in
hearts, resulting in age-associated cardiac hypertrophy.69
Deletion of the IGF-1R resulted in reduced hypertrophy,
and fibrosis was reduced in aged IGF-1R/ mice compared
with aged wild-type controls.69 Furthermore, IGF-1R/
hearts had an attenuation of age-related proinflammatory
cytokines (IL-1a, IL-1b, IL-6, and receptor activator of nu-
clear factor k-B ligand).69 In cultured cardiomyocytes, IGF-1
induction of senescence evidence has been reported, evi-
denced by increased b-galactosidase staining (inhibited by
phosphoinositide 3-kinase inhibitor).69 Despite these poten-
tial benefits of inhibiting IGF-1 signaling in the atrogin-1
Tgþ hearts, IGF-1 receptor haploinsufficiency can
contribute to age-dependent development of metabolic syn-
drome in skeletal muscle, so it should be considered as a
system-wide target to aging-associated changes in striated
muscle.70
The role of atrogin-1 in regulating autophagy was recently
discovered, with atrogin-1/ mouse heart developing car-
diomyopathy and premature death, including significantly
increased fibrosis.17 In these studies, in vivo pulsing of stable
isotope labeling amino acids in cell culture proteomics
revealed increases in the CHMP2B, which is part of
the endosomal sorting complex required for autophagy.17
Atrogin-1/ mice with increased CHMP2B protein had
impaired autophagy, accumulation of aggregates, and activa-
tion of the unfolded protein response, which increased pro-
gressively with age.17 In the current study, we identified that
atrogin-1 Tgþ hearts have significant increases in CHMP2B
protein in 18-montheold mouse hearts (Figure 6C), which
may indicate that the enhanced degradation expected with
increased atrogin-1 is counteracted by other regulatory
mechanisms. The increased protein levels may be because of
increased transcription, and not enhanced degradation,
because multiple transcription factors have binding sites in
the CHMP2B gene promoter, including AREB6, POU3F1,
USF1, USF2, Sox9, and POU3F2 (GeneCards identification:
GC03P087277). Although there is limited information on any
links between autophagy and fibrosis, the present studymay be
the first to demonstrate a link between the increased atrogin-1
Tgþ mediated CHMP2B protein levels with the observed
decrease in collagen accumulation. In support of this notion,
liver fibrosis was suppressed by the direct inhibition of
Beclin1-mediated autophagy.71
Cardiomyocyte proliferation and growth during
development is regulated by FoxO1/FoxO3 transcription
factors.72 However, myocyte-specific transgenic expression
of FoxO1 during heart development leads to decreased
myocyte proliferation and lethality.72 In contrast, dominant
negative FoxO1 in cardiomyocytes leads to increased
myocyte proliferation.72 In the present study, we identified a
significant increase in atrogin-1 Tgþ nuclei density
compared with wild-type hearts (Figure 2, E and F) without
alterations in fibroblasts (Figure 3). Because the a-major
histocompatibility complex expression predominates
after birth, at which stage myocytes are binucleate,73e75
the effects of increasing atrogin-1 with age may alter
cardiomyocyte number in an unpredictable manner.
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